For two decades, precision medicine has been the future of oncology treatment. We aim to fulfill the promise.

To date, more than 10,000 cancer genomes have been decoded, uncovering thousands of recurrent mutations known to be important drivers of cancer. Yet with a handful of exceptions, the vast majority of these genetic drivers of cancer remain out of reach for drug development. They are considered “undruggable” by current methods or too poorly understood for intervention.

As a result, the vast majority of cancers today are treated as they have been for decades and the genomic revolution remains an abstract concept to millions of people diagnosed and treated for cancer every year.
We aim to change that.

Our vision is a world in which precision medicine is the first choice for most people diagnosed with cancer.

We are executing a three-pronged attack to chase our vision: we are creating a new generation of best or first-in-class drugs against known cancer drivers; we are going after elusive targets in new ways; and we are discovering and rapidly drugging novel targets, with the potential to transform treatment paradigms for both common and rare forms of cancer.